Quick Search 
Drugs of the Future
Register or sign in

Volume 36, Issue 5, May 2011, Pages 351-422
Sodium/glucose cotransporter 2 inhibitor, Treatment of type 2 diabetes, Treatment of obesity.
Chao, E.C.
Drugs Fut 2011, 36(5): 351
Summary | Full Text: HTMLPDF 
Vasopressin V2 receptor antagonist, Treatment of heart failure, Treatment of hyponatremia.
Daifallah, S., Zmily, H.D., Alqwasmi, A.H., Zayed, H., Ghali, J.K.
Drugs Fut 2011, 36(5): 359
Summary | Full Text: HTMLPDF 
Androgen receptor antagonist, Prostate cancer therapy.
Gao, L., Alumkal, J.
Drugs Fut 2011, 36(5): 371
Summary | Full Text: HTMLPDF 
 Cholesteryl ester transfer protein (CEPT) inhibitors and their role in cardiovascular disorders.
Kontush, A.
Drugs Fut 2011, 36(5): 377
Summary | Full Text: HTMLPDF 
 Combretastatin derivatives in cancer: recent research reviewed.
Pattillo, C.B.
Drugs Fut 2011, 36(5): 385
Summary | Full Text: HTMLPDF 
 HIF regulation in tumor progression and angiogenesis and potential therapeutic agents.
Podar, K.
Drugs Fut 2011, 36(5): 391
Summary | Full Text: HTMLPDF 
 Erdheim–Chester disease: new advances.
Haddley, K.
Drugs Fut 2011, 36(5): 403
Summary | Full Text: HTMLPDF 
 Epigenetics: highlights of the Society for Medicines Research Symposium, held on September 22, 2010, London, UK.
Armer, R., Coe, D., Jeffrey, P., Lock, R.
Drugs Fut 2011, 36(5): 409
Summary | Full Text: HTMLPDF 
 Highlights from the 9th International Symposium on Targeted Anticancer Therapies (March 7-9, 2011 – Paris, France).
Rabasseda, X.
Drugs Fut 2011, 36(5): 415
Summary | Full Text: HTMLPDF 
 Drugs Fut 2011, 36(5): 422
Full Text: PDF Related article: HTML  PDF 

© 2020 Clarivate Analytics. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie Policy